Brodalumab
Interleukin Inhibitors
Sold as Kyntheum · SILIQ
- Drug class
- Interleukin Inhibitors
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 3
- Products on record
- 3
Overview
Brodalumab is an active pharmaceutical ingredient in the Interleukin Inhibitors group (L04AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | May 15, 2026 |
| EU European Union | EMA | 1 | August 27, 2025 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
GBUnited Kingdom· MHRA
1 product
Uses
Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
How to take
EUEuropean Union· EMA
1 product
Uses
Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
How to take
CACanada· Health Canada
1 product
Uses
• SILIQ brodalumab injection) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. 1 Pediatrics (< 18 years of age) The safety and efficacy of SILIQ in children below the age of 18 years have not yet been established.
No data are available. 2 Geriatrics (≥ 65 years of age) No dose adjustment is recommended in geriatric patients (see 10 CLINICAL PHARMACOLOGY).
How to take
Drug interactions
Known interactions involving Brodalumab. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB052930171 · revised May 15, 2026
- [2]European Medicines Agency · EMEA/H/C/003959 · revised August 27, 2025
- [3]Health Canada (DPD) · 02473623 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.